Drugs / Lampalizumab
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00973011 | Sep 2009 → Jul 2010 | diffuse secondary choroid atrophy | Genentech, Inc. | Completed | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT02288559 | Mar 2015 → Jun 2017 | diffuse secondary choroid atrophy | Genentech, Inc. | Completed | Missed primary |
| Phase 2 | NCT01602120 | May 2012 → Nov 2017 | diffuse secondary choroid atrophy | Genentech, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT01229215 | Feb 2011 → Apr 2013 | diffuse secondary choroid atrophy | Genentech, Inc. | Completed | No outcome recorded |
| Phase 33 trials · 2 missed | ||||||
| Phase 3 | NCT02745119 | Jul 2016 → Jan 2018 | diffuse secondary choroid atrophy | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 3 | NCT02247531 | Oct 2014 → Jan 2018 | diffuse secondary choroid atrophy | Hoffmann-La Roche | Terminated | Missed primary |
| Phase 3 | NCT02247479 | Sep 2014 → Jan 2018 | diffuse secondary choroid atrophy | Hoffmann-La Roche | Terminated | Missed primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2017-09-08 | Hoffmann-La Roche | Results Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration roche.com ↗
Lampalizumab did not reduce mean change in GA lesion area compared to sham treatment at 1 year (48 weeks). |
| 2017-09-08 | Genentech, Inc. | Results Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration gene.com ↗
today announced that the primary endpoint has not been met in Spectri, the first of two Phase III studies evaluating the safety and efficacy of lampalizumab |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-09-08 | Hoffmann-La Roche | Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration roche.com ↗ |
| 2017-09-08 | Genentech, Inc. | Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration gene.com ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lampalizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02247531 ↗ |
| Known as | anti-FACTOR-D | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109408 ↗ |
| Known as | Anti-fD | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109408 ↗ |
| Known as | FCFD4514S | “A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab (FCFD4514S) in Patients With Geographic Atrophy Who Have Completed...” NCT01602120 ↗ |
| Known as | RG-7417 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109408 ↗ |
| Known as | Sn578b8z9q | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109408 ↗ |
| Action | Inhibit | “lampalizumab, a selective complement factor D inhibitor” PMID 29801123 ↗ Jun 20181“Complement factor D inhibitor” CHEMBL2109408 ↗ |
| Modality | Monoclonal antibody | — CHEMBL2109408 ↗ |
| Route | Intravitreal | “Intravitreal escalating dose” NCT00973011 ↗ |
| Target | CFD | “Complement factor D inhibitor” CHEMBL2109408 ↗ |